Idexx Laboratories, Inc. (IDXX)

$469.71

-0.97

(-0.21%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $468.00
    $476.15
    $469.71
    downward going graph

    0.36%

    Downside

    Day's Volatility :1.71%

    Upside

    1.35%

    downward going graph
  • $372.50
    $583.39
    $469.71
    downward going graph

    20.7%

    Downside

    52 Weeks Volatility :36.15%

    Upside

    19.49%

    downward going graph

Returns

PeriodIdexx Laboratories, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-5.73%
6.5%
7.9%
6 Months
-10.34%
7.1%
11.2%
1 Year
-15.37%
9.8%
21.6%
3 Years
-31.35%
14.2%
15.8%

Highlights

Market Capitalization
38.8B
Book Value
$18.93
Earnings Per Share (EPS)
10.3
PE Ratio
45.67
PEG Ratio
4.75
Wall Street Target Price
556.54
Profit Margin
23.26%
Operating Margin TTM
31.01%
Return On Assets TTM
22.63%
Return On Equity TTM
71.91%
Revenue TTM
3.7B
Revenue Per Share TTM
44.83
Quarterly Revenue Growth YOY
7.1%
Gross Profit TTM
2.0B
EBITDA
1.2B
Diluted Eps TTM
10.3
Quarterly Earnings Growth YOY
0.1
EPS Estimate Current Year
11.06
EPS Estimate Next Year
12.54
EPS Estimate Current Quarter
2.67
EPS Estimate Next Quarter
2.99

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Idexx Laboratories, Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 18.49%

Current $469.71
Target $556.54

Company Financials

FY18Y/Y Change
Revenue
2.2B
↑ 12.4%
Net Income
377.0M
↑ 43.28%
Net Profit Margin
17.04%
↑ 3.68%
FY19Y/Y Change
Revenue
2.4B
↑ 8.75%
Net Income
427.7M
↑ 13.44%
Net Profit Margin
17.77%
↑ 0.73%
FY20Y/Y Change
Revenue
2.7B
↑ 12.45%
Net Income
581.8M
↑ 36.02%
Net Profit Margin
21.49%
↑ 3.72%
FY21Y/Y Change
Revenue
3.2B
↑ 18.79%
Net Income
744.8M
↑ 28.03%
Net Profit Margin
23.17%
↑ 1.68%
FY22Y/Y Change
Revenue
3.4B
↑ 4.73%
Net Income
679.1M
↓ 8.83%
Net Profit Margin
20.17%
↓ 3.0%
FY23Y/Y Change
Revenue
3.7B
↑ 8.72%
Net Income
845.0M
↑ 24.44%
Net Profit Margin
23.08%
↑ 2.91%
Q4 FY22Q/Q Change
Revenue
828.6M
↓ 1.56%
Net Income
172.2M
↓ 4.83%
Net Profit Margin
20.78%
↓ 0.72%
Q1 FY23Q/Q Change
Revenue
900.2M
↑ 8.64%
Net Income
214.1M
↑ 24.3%
Net Profit Margin
23.78%
↑ 3.0%
Q2 FY23Q/Q Change
Revenue
943.6M
↑ 4.83%
Net Income
224.2M
↑ 4.76%
Net Profit Margin
23.76%
↓ 0.02%
Q3 FY23Q/Q Change
Revenue
915.5M
↓ 2.98%
Net Income
212.2M
↓ 5.35%
Net Profit Margin
23.18%
↓ 0.58%
Q4 FY23Q/Q Change
Revenue
901.6M
↓ 1.52%
Net Income
194.5M
↓ 8.34%
Net Profit Margin
21.58%
↓ 1.6%
Q1 FY24Q/Q Change
Revenue
964.1M
↑ 6.93%
Net Income
235.6M
↑ 21.11%
Net Profit Margin
24.44%
↑ 2.86%
FY18Y/Y Change
Total Assets
1.5B
↓ 10.28%
Total Liabilities
1.5B
↓ 12.49%
FY19Y/Y Change
Total Assets
1.8B
↑ 19.2%
Total Liabilities
1.7B
↑ 6.99%
FY20Y/Y Change
Total Assets
2.3B
↑ 25.22%
Total Liabilities
1.7B
↑ 0.43%
FY21Y/Y Change
Total Assets
2.4B
↑ 6.22%
Total Liabilities
1.7B
↑ 5.14%
FY22Y/Y Change
Total Assets
2.7B
↑ 12.7%
Total Liabilities
2.1B
↑ 22.37%
FY23Y/Y Change
Total Assets
3.3B
↑ 18.68%
Total Liabilities
1.8B
↓ 16.96%
Q4 FY22Q/Q Change
Total Assets
2.7B
↑ 4.04%
Total Liabilities
2.1B
↓ 1.2%
Q1 FY23Q/Q Change
Total Assets
2.8B
↑ 2.24%
Total Liabilities
2.0B
↓ 7.99%
Q2 FY23Q/Q Change
Total Assets
2.9B
↑ 2.22%
Total Liabilities
1.8B
↓ 9.68%
Q3 FY23Q/Q Change
Total Assets
3.1B
↑ 7.51%
Total Liabilities
1.8B
↑ 0.68%
Q4 FY23Q/Q Change
Total Assets
3.3B
↑ 5.62%
Total Liabilities
1.8B
↓ 0.76%
Q1 FY24Q/Q Change
Total Assets
3.4B
↑ 2.87%
Total Liabilities
1.8B
↑ 0.52%
FY18Y/Y Change
Operating Cash Flow
400.1M
↑ 7.18%
Investing Cash Flow
138.6M
↓ 199.94%
Financing Cash Flow
-597.8M
↑ 187.38%
FY19Y/Y Change
Operating Cash Flow
459.2M
↑ 14.77%
Investing Cash Flow
-205.5M
↓ 248.29%
Financing Cash Flow
-286.4M
↓ 52.09%
FY20Y/Y Change
Operating Cash Flow
648.1M
↑ 41.14%
Investing Cash Flow
-109.4M
↓ 46.78%
Financing Cash Flow
-248.4M
↓ 13.27%
FY21Y/Y Change
Operating Cash Flow
755.5M
↑ 16.59%
Investing Cash Flow
-293.0M
↑ 167.85%
Financing Cash Flow
-697.4M
↑ 180.74%
FY22Y/Y Change
Operating Cash Flow
543.0M
↓ 28.13%
Investing Cash Flow
-195.4M
↓ 33.32%
Financing Cash Flow
-370.9M
↓ 46.81%
Q4 FY22Q/Q Change
Operating Cash Flow
173.4M
↓ 8.24%
Investing Cash Flow
-49.2M
↑ 0.07%
Financing Cash Flow
-116.7M
↓ 21.57%
Q1 FY23Q/Q Change
Operating Cash Flow
183.9M
↑ 6.05%
Investing Cash Flow
-39.5M
↓ 19.74%
Financing Cash Flow
-146.1M
↑ 25.16%
Q2 FY23Q/Q Change
Operating Cash Flow
200.3M
↑ 8.92%
Investing Cash Flow
-27.5M
↓ 30.48%
Financing Cash Flow
-151.0M
↑ 3.39%

Technicals Summary

Sell

Neutral

Buy

Idexx Laboratories, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Idexx Laboratories, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 901.60M → 964.09M (in $), with an average increase of 6.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 194.52M → 235.57M (in $), with an average increase of 17.4% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 20.5%

  • Vs TMO

    In the last 3 years, Idexx Laboratories, Inc. has experienced a drawdown of -31.4%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 21.2%

Institutional Holdings

  • BlackRock Inc

    11.15%

  • Vanguard Group Inc

    10.26%

  • State Street Corporation

    4.58%

  • AllianceBernstein L.P.

    3.62%

  • Fundsmith LLP

    3.29%

  • Geode Capital Management, LLC

    2.61%

Company Information

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Organization
Idexx Laboratories, Inc.
Employees
11000
CEO
Mr. Jonathan J. Mazelsky
Industry
Health Technology

Discover More

FAQs